China SXT Pharmaceuticals, Inc.
SXTC
$1.50
$0.021.35%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.74M | 1.78M | 1.82M | 1.87M | 1.93M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.74M | 1.78M | 1.82M | 1.87M | 1.93M |
| Cost of Revenue | 1.37M | 1.40M | 1.42M | 1.40M | 1.37M |
| Gross Profit | 367.40K | 383.90K | 400.40K | 477.20K | 554.00K |
| SG&A Expenses | 3.05M | -1.59M | -6.22M | -1.79M | 2.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.42M | -189.30K | -4.80M | -389.60K | 4.02M |
| Operating Income | -2.68M | 1.97M | 6.62M | 2.26M | -2.09M |
| Income Before Tax | -3.30M | 1.25M | 5.80M | 1.35M | -3.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.30 | 1.25 | 5.80 | 1.35 | -3.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.30M | 1.25M | 5.80M | 1.35M | -3.10M |
| EBIT | -2.68M | 1.97M | 6.62M | 2.26M | -2.09M |
| EBITDA | -2.60M | 2.09M | 6.79M | 2.45M | -1.89M |
| EPS Basic | -3.01 | 18.90 | 40.81 | -35.54 | -111.89 |
| Normalized Basic EPS | -1.88 | 12.67 | 27.22 | -20.50 | -68.22 |
| EPS Diluted | -3.01 | 18.90 | 40.81 | -35.54 | -111.89 |
| Normalized Diluted EPS | -1.88 | 12.67 | 27.22 | -20.50 | -68.22 |
| Average Basic Shares Outstanding | 5.69M | 3.40M | 1.12M | 775.00K | 433.80K |
| Average Diluted Shares Outstanding | 5.69M | 3.40M | 1.12M | 775.00K | 433.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |